Cargando…
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Activation of the ERK pathway is a hallmark of cancer and targeting of upstream signalling partners led to the development of approved drugs. Recently SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor. Here we report the structural mechanism for its remarkable selectivity. In ER...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687050/ https://www.ncbi.nlm.nih.gov/pubmed/25195011 http://dx.doi.org/10.1038/nchembio.1629 |